Ítem
Solo Metadatos

HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine

Mostrar el registro sencillo de la publicación
dc.creatorJoura, Elmar A.spa
dc.creatorKjaer, Susanne K.spa
dc.creatorWheeler, Cosette M.spa
dc.creatorSigurdsson, Kristjánspa
dc.creatorIversen, Ole-Erikspa
dc.creatorHernandez-Avila, Mauriciospa
dc.creatorPerez, Gonzalospa
dc.creatorBrown, Darron R.spa
dc.creatorKoutsky, Laura A.spa
dc.creatorTay, Eng Hseonspa
dc.creatorGarcía, Patriciaspa
dc.creatorAult, Kevin A.spa
dc.creatorGarland, Suzanne M.spa
dc.creatorLeodolter, Seppspa
dc.creatorOlsson, Sven-Ericspa
dc.creatorTang, Grace W.K.spa
dc.creatorFerris, Daron G.spa
dc.creatorPaavonen, Jormaspa
dc.creatorLehtinen, Mattispa
dc.creatorSteben, Marcspa
dc.creatorBosch, Xavierspa
dc.creatorDillner, Joakimspa
dc.creatorKurman, Robert J.spa
dc.creatorMajewski, Slawomirspa
dc.creatorMuñoz, Nubiaspa
dc.creatorMyers, Evan R.spa
dc.creatorVilla, Luisa L.spa
dc.creatorTaddeo, Frank J.spa
dc.creatorRoberts, Christinespa
dc.creatorTadesse, Amhaspa
dc.creatorBryan, Janinespa
dc.creatorLupinacci, Lisa C.spa
dc.creatorGiacoletti, Katherine E.D.spa
dc.creatorLu, Shuangspa
dc.creatorVuocolo, Scottspa
dc.creatorHesley, Teresa M.spa
dc.creatorHaupt, Richard M.spa
dc.creatorBarr, Eliavspa
dc.date.accessioned2020-05-26T00:02:06Z
dc.date.available2020-05-26T00:02:06Z
dc.date.created2008spa
dc.description.abstractThe efficacy of the quadrivalent Human Papillomavirus (HPV) vaccine is thought to be mediated by humoral immunity. We evaluated the correlation between quadrivalent HPV vaccine-induced serum anti-HPV responses and efficacy. 17,622 women were vaccinated at day 1, and months 2 and 6. At day 1 and at 6-12 months intervals for up to 48 months, subjects underwent Papanicolaou and genital HPV testing. No immune correlate of protection could be found due to low number of cases. Although 40% of vaccine subjects were anti-HPV 18 seronegative at end-of-study, efficacy against HPV 18-related disease remained high (98.4%; 95% CI: 90.5-100.0) despite high attack rates in the placebo group. These results suggest vaccine-induced protection via immune memory, or lower than detectable HPV 18 antibody titers. © 2008 Elsevier Ltd. All rights reserved.eng
dc.format.mimetypeapplication/pdf
dc.identifier.doihttps://doi.org/10.1016/j.vaccine.2008.09.073
dc.identifier.issn0264410X
dc.identifier.issn13588745
dc.identifier.urihttps://repository.urosario.edu.co/handle/10336/23448
dc.language.isoengspa
dc.relation.citationEndPage6851
dc.relation.citationIssueNo. 52
dc.relation.citationStartPage6844
dc.relation.citationTitleVaccine
dc.relation.citationVolumeVol. 26
dc.relation.ispartofVaccine, ISSN:0264410X, 13588745, Vol.26, No.52 (2008); pp. 6844-6851spa
dc.relation.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-56949087305&doi=10.1016%2fj.vaccine.2008.09.073&partnerID=40&md5=d26d764753441b12cfbb7a520688ce75spa
dc.rights.accesRightsinfo:eu-repo/semantics/openAccess
dc.rights.accesoAbierto (Texto Completo)spa
dc.source.instnameinstname:Universidad del Rosariospa
dc.source.reponamereponame:Repositorio Institucional EdocURspa
dc.subject.keywordPlacebospa
dc.subject.keywordSilgardspa
dc.subject.keywordUnclassified drugspa
dc.subject.keywordVirus antibodyspa
dc.subject.keywordWart virus vaccinespa
dc.subject.keywordAdolescentspa
dc.subject.keywordAdultspa
dc.subject.keywordAntibody productionspa
dc.subject.keywordAntibody responsespa
dc.subject.keywordArticlespa
dc.subject.keywordCancer immunizationspa
dc.subject.keywordCancer preventionspa
dc.subject.keywordClinical trialspa
dc.subject.keywordControlled clinical trialspa
dc.subject.keywordControlled studyspa
dc.subject.keywordDouble blind procedurespa
dc.subject.keywordDrug efficacyspa
dc.subject.keywordFemalespa
dc.subject.keywordHumanspa
dc.subject.keywordInfection preventionspa
dc.subject.keywordMajor clinical studyspa
dc.subject.keywordPhase 3 clinical trialspa
dc.subject.keywordPriority journalspa
dc.subject.keywordRandomized controlled trialspa
dc.subject.keywordUterine cervix carcinoma in situspa
dc.subject.keywordWart virusspa
dc.subject.keywordAdolescentspa
dc.subject.keywordAntibodieseng
dc.subject.keywordCondylomata acuminataspa
dc.subject.keywordFemalespa
dc.subject.keywordFollow-up studiesspa
dc.subject.keywordHuman papillomavirus 11spa
dc.subject.keywordHuman papillomavirus 16spa
dc.subject.keywordHuman papillomavirus 18spa
dc.subject.keywordHuman papillomavirus 6spa
dc.subject.keywordHumansspa
dc.subject.keywordImmunization schedulespa
dc.subject.keywordPapillomavirus infectionsspa
dc.subject.keywordPapillomavirus vaccinesspa
dc.subject.keywordReverse transcriptase polymerase chain reactionspa
dc.subject.keywordVaginaspa
dc.subject.keywordVaginal smearsspa
dc.subject.keywordVulvaspa
dc.subject.keywordYoung adultspa
dc.subject.keywordHuman papillomavirusspa
dc.subject.keywordHumoral immunityspa
dc.subject.keywordImmune memoryspa
dc.titleHPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccinespa
dc.typearticleeng
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersion
dc.type.spaArtículospa
Archivos
Colecciones
Artículos